Tekcapital Investee Files Patent For Coronavirus Treatment

(Alliance News) - Tekcapital PLC said Monday its investee, Belluscura PLC, has filed for a patent ...

Alliance News 10 February, 2020 | 9:20AM
Email Form

(Alliance News) - Tekcapital PLC said Monday its investee, Belluscura PLC, has filed for a patent application for an oxygen enrichment device that treats acute respiratory distress.

Shares in the intellectual property investor were 13% higher in London on Monday morning at 5.46 pence each.

Tekcapital noted the device can treat patients suffering from the deadly coronavirus.

"The primary cause of death from respiratory viruses like the coronavirus and influenza, are the result of the fluids accumulating inside the alveoli (the tiny air sacs of the lungs) which ultimately leads to the failure of the transfer of oxygen to and carbon dioxide out of the blood. The current primary treatment for ARDS is oxygen therapy along with ventilator support," Tekcapital explained.

Belluscura, along with its research partner Separation Design Group, filed the patent application that covers novel integrated portable extracorporeal oxygenation and carbon dioxide removal systems.

Tekcapital Chair Clilfford Gross said: "We are pleased to see the additional progress of Belluscura as it continues to strengthen its intellectual property in the oxygen therapy space to help patients afflicted with acute respiratory distress caused by the Coronavirus. Additionally, we anticipate that Belluscura is likely to receive FDA clearance for their portable oxygen concentrator within the next 90 days."

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Tekcapital PLC 5.11 GBX 1.21 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites